[Clinico-laboratory assessment of oframax (cefriaxone) in the treatment of infectious-inflammatory diseases].
OBJECTIVE
To try efficacy and safety of ophramax (cephtriaxon) made in India ("Ranbaxy") in infectious-inflammatory diseases treated in a general hospital.


METHODS
Ophramax was given in a dose 1 to 4 g/day to 23 patients with pneumonia, chronic bronchitis, soft tissue infection, enterocolitis, etc. Therapeutic effect was examined with bacteriological identification of the infective agents, antibioticograms, agar diffusion test.


RESULTS
High sensitivity of pathogens to ophramax was observed in bronchopulmonary diseases (90.7%). In other infections sensitivity of the pathogens was 59.3%. Enterococci were the only highly resistant pathogens (40.5%). Ophramax remains in the body in sufficiently high concentrations for 24 hours. This attributes to good therapeutic effect.


CONCLUSIONS
Clinico-microbiological and pharmacokinetic findings show that ophramax can be used as a basic drug for treatment of different infectious-inflammatory diseases. Once-a-day regimen is a great advantage of ophramax.
Sokolova
V I
VI
Orlov
V A
VA
Shenderovich
V A
VA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016903:Drug Monitoring; D024881:Drug Resistance, Bacterial; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008875:Middle Aged
D002511:Cephalosporins; D002443:Ceftriaxone